In particular, in a human study, the transfer of intestinal microbiota from lean donors increased insulin sensitivity in individuals with metabolic syndrome along with levels of butyrate-producing intestinal microbiota, suggesting that intestinal microbiota should be developed as therapeutic agents for increasing insulin sensitivity in humans [74]. Here, INS is linked to metabolic syndrome.